Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70051 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Xiaofei Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Benzofurans, Quinazolines, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Fruquintinib is a highly selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved by the US Food and Drug Administration and the European Commission for the treatment of previously treated metastatic colorectal cancer (mCRC), regardless of biomarker status. This study used concentration QT interval (C‐QTc) modeling, utilizing data from the phase 3 FRESCO‐2 study (NCT04322539) in which patients with mCRC received fruquintinib 5 mg, once daily, or matching placebo in a 28‐day cycle, to evaluate the potential of fruquintinib to delay cardiac repolarization. The primary objectives were to assess the relationship between change from baseline in the QTc and plasma concentrations of fruquintinib and its metabolite M11, and to predict placebo‐corrected change from baseline in the corrected QT interval (ΔΔQTc) associated with clinically relevant fruquintinib or M11 concentrations. The C‐QTc analysis was conducted using 1456 time‐matched concentration‐change from baseline in the population‐based corrected QT interval (ΔQTcP) pairs from 205 patients (fruquintinib n = 137; placebo n = 68). The final C‐QTc model was a linear mixed‐effects model with the effect of M11 concentration on ΔQTcP. This model estimated that the upper bounds of the 90% CI of the mean ΔΔQTcP at steady‐state geometric mean (GM) M11 C max, and twice the GM M11 C max were 0.0537 and 4.00 ms, respectively. Additional C‐QTc analysis, including only fruquintinib concentrations, showed no relationship between ΔQTcP and fruquintinib concentrations. The analysis indicated that fruquintinib administered at the approved clinical dose is not anticipated to cause clinically meaningful QT prolongation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA.
- Certara, Radnor, PA, USA.
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- HUTCHMED International Corporation, Florham Park, NJ, USA.
ORCID-Profile: Xiaofei Zhou, Adekemi Taylor
Zitieren
APA
Zhou, X., Toms, A., Morton, D., Wang, X., Taylor, A., Dasari, A., Gupta, N., & Chien, C. (2025). Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70051
Vancouver
Zhou X, Toms A, Morton D, Wang X, Taylor A, Dasari A, et al. Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70051
BibTeX
@article{Zhou2025,
author = {Zhou, Xiaofei and Toms, Alice and Morton, Dave and Wang, Xiaohui and Taylor, Adekemi and Dasari, Arvind and Gupta, Neeraj and Chien, Caly},
title = {Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70051}
}
EUVIMED